Literature DB >> 34484888

Health Care Utilization and Costs in Patients With Migraine Who Have Failed Previous Preventive Treatments.

Lawrence Newman1, Pamela Vo1, Lujia Zhou1, Cristina Lopez Lopez1, Andy Cheadle1, Melvin Olson1, Juanzhi Fang1.   

Abstract

OBJECTIVE: To characterize health care utilization (HCU) and associated costs among patients with migraine categorized by the number of preventive treatment failures (TFs; 1 TF, 2 TFs, and 3+ TFs) using real-world data.
METHODS: This retrospective analysis identified adults with incident migraine diagnosis in the IBM MarketScan Commercial and Medicare Supplemental database between January 1, 2011, and June 30, 2015. TF was defined in the 2 years after the first migraine diagnosis period. One TF, 2 TFs, and 3+ TFs were defined as patients who had received only 2 preventive treatments (PTs), 3 PTs, and 4+ PTs in the 2-year period, respectively. A negative binomial model was used to analyze HCU data, and a 2-part model was used for cost data controlling for the preindex Deyo-Charlson Comorbidity Index.
RESULTS: Overall, 24,282 patients with incident migraine who had failed at least 1 PT were included in the analysis. Of these, 72.7% (n = 17,653) had 1 TF, 20.2% (n = 4,900) had 2 TFs, and 7.1% (n = 1,729) had 3+ TFs. Adjusted annualized rates of all-cause and migraine-specific HCU increased with an increase in the number of TFs (1.4-4 times higher; all p < 0.0001 vs 1 TF). The mean total all-cause health care costs were higher by $3,732 (95% confidence interval [CI]: $2,708-$4,588) in patients with 2 TFs and by $8,912 (95% CI: $7,141-$10,822) in patients with 3+ TFs vs those with 1 TF. Outpatient costs were the key drivers of differences in health care costs.
CONCLUSIONS: TF in patients with migraine was associated with a substantial resource and cost burden, which increased with the number of TFs.
© 2021 American Academy of Neurology.

Entities:  

Year:  2021        PMID: 34484888      PMCID: PMC8382370          DOI: 10.1212/CPJ.0000000000001076

Source DB:  PubMed          Journal:  Neurol Clin Pract        ISSN: 2163-0402


  18 in total

1.  Cost of healthcare for patients with migraine in five European countries: results from the International Burden of Migraine Study (IBMS).

Authors:  L M Bloudek; M Stokes; D C Buse; T K Wilcox; R B Lipton; P J Goadsby; S F Varon; A M Blumenfeld; Z Katsarava; J Pascual; M Lanteri-Minet; P Cortelli; P Martelletti
Journal:  J Headache Pain       Date:  2012-05-29       Impact factor: 7.277

2.  The American Headache Society Position Statement On Integrating New Migraine Treatments Into Clinical Practice.

Authors: 
Journal:  Headache       Date:  2018-12-10       Impact factor: 5.887

3.  Direct and Indirect Costs Among United States Commercially Insured Employees With Migraine.

Authors:  Adrienne M Gilligan; Shonda A Foster; Amy Sainski-Nguyen; Robert Sedgley; David Smith; Paula Morrow
Journal:  J Occup Environ Med       Date:  2018-12       Impact factor: 2.162

Review 4.  Evidence-based guideline update: pharmacologic treatment for episodic migraine prevention in adults: report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society.

Authors:  S D Silberstein; S Holland; F Freitag; D W Dodick; C Argoff; E Ashman
Journal:  Neurology       Date:  2012-04-24       Impact factor: 9.910

5.  The burden of migraine in the United States: current and emerging perspectives on disease management and economic analysis.

Authors:  Elisabeth Hazard; Julie Munakata; Marcelo E Bigal; Marcia F T Rupnow; Richard B Lipton
Journal:  Value Health       Date:  2008-07-30       Impact factor: 5.725

6.  Direct and Indirect Costs of Chronic and Episodic Migraine in the United States: A Web-Based Survey.

Authors:  Andrew Messali; Joanna C Sanderson; Andrew M Blumenfeld; Peter J Goadsby; Dawn C Buse; Sepideh F Varon; Michael Stokes; Richard B Lipton
Journal:  Headache       Date:  2016-02-01       Impact factor: 5.887

7.  Burden of migraine in Finland: health care resource use, sick-leaves and comorbidities in occupational health care.

Authors:  Minna A Korolainen; Samu Kurki; Mariann I Lassenius; Iiro Toppila; Madlaina Costa-Scharplatz; Timo Purmonen; Markku Nissilä
Journal:  J Headache Pain       Date:  2019-02-12       Impact factor: 7.277

8.  Comorbid and co-occurring conditions in migraine and associated risk of increasing headache pain intensity and headache frequency: results of the migraine in America symptoms and treatment (MAST) study.

Authors:  Dawn C Buse; Michael L Reed; Kristina M Fanning; Ryan Bostic; David W Dodick; Todd J Schwedt; Sagar Munjal; Preeti Singh; Richard B Lipton
Journal:  J Headache Pain       Date:  2020-03-02       Impact factor: 7.277

9.  My Migraine Voice survey: a global study of disease burden among individuals with migraine for whom preventive treatments have failed.

Authors:  Paolo Martelletti; Todd J Schwedt; Michel Lanteri-Minet; Rebeca Quintana; Veruska Carboni; Hans-Christoph Diener; Elena Ruiz de la Torre; Audrey Craven; Annette Vangaa Rasmussen; Simon Evans; Annik K Laflamme; Rachel Fink; Donna Walsh; Paula Dumas; Pamela Vo
Journal:  J Headache Pain       Date:  2018-11-27       Impact factor: 7.277

10.  Cost of chronic and episodic migraine patients in continuous treatment for two years in a tertiary level headache Centre.

Authors:  Andrea Negro; Paolo Sciattella; Daniele Rossi; Martina Guglielmetti; Paolo Martelletti; Francesco Saverio Mennini
Journal:  J Headache Pain       Date:  2019-12-30       Impact factor: 7.277

View more
  1 in total

1.  Real-world effectiveness after initiating fremanezumab treatment in US patients with episodic and chronic migraine or difficult-to-treat migraine.

Authors:  Maurice T Driessen; Joshua M Cohen; Stephen F Thompson; Oscar Patterson-Lomba; Michael J Seminerio; Karen Carr; Todor I Totev; Rochelle Sun; Erica Yim; Fan Mu; Rajeev Ayyagari
Journal:  J Headache Pain       Date:  2022-05-16       Impact factor: 8.588

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.